PURE Bioscience Appoints Dave Pfanzelter Chairman of the Board

PURE Bioscience Appoints Dave Pfanzelter Chairman of the Board 
PURE Strengthens Corporate Governance While Cutting Costs 
SAN DIEGO, CA -- (Marketwired) -- 05/17/13 --   PURE Bioscience
(OTCQB: PURE), creator of the patented silver dihydrogen citrate
(SDC) antimicrobial, appointed food industry leader Dave Pfanzelter
as chairman of the board. Pfanzelter has been a member of the board
since February 2013 and had previously served on the PURE Bioscience
Advisory Panel. The position of chairman had been held by PURE's
president and CEO, Michael L. Krall, since 1993. 
Pfanzelter previously served as senior vice president of Kellogg
Company, president of Kellogg's Specialty Channels, and president of
Kellogg Canada while also serving as part of the Kellogg Executive
Committee and Global Leadership Team. He has also served on the board
of the International Food Service Manufacturer's Association as
chairman and a member of its executive committee. Pfanzelter
currently serves on the board of directors of Doctor's Associates,
the parent company of Subway Restaurants, as well as on Wrigley
Foods' Advisory Board of Directors. 
Pfanzelter stated: "I am honored to be named chairman of PURE's
board. The company has endured a rough road during the extensive
processes of R&D, regulatory approvals and product development and is
engaged in notably long sales cycles. Despite these challenges, the
board remains confident in PURE's ability to overcome the high hurdle
of market acceptance. I look forward to working closely with Michael
and the PURE management team." 
Krall added: "Dave is a great fit for the future of SDC and PURE
Bioscience, and I welcome the opportunity to expand our leadership
resources while strengthening our corporate governance. Dave's
extensive experience is invaluable to PURE as we move through the
final steps of evaluation by several key potential customers,
including those in the food industry and within the military." 
"We acknowledge the need to right-size our organization while still
moving aggressively toward closing sales in our target markets yet
staying nimble enough to successfully operate the business,"
continued Krall. "To that end, we have reduced costs and personnel in
all departments other than sales and marketing as we continue the
push toward meaningful revenues. We've also established high-capacity
outsourcing options for manufacturing to remain positioned to timely
fill orders as necessary." 
PURE has cut total wage expenditures by more than 30% through the
elimination of manufacturing, research and development,
administrative and executive positions. The company has also reduced
G&A expenses related to professional services, including legal and
consulting fees, public relations and investor relations.
Furthermore, PURE's corporate officers and directors have elected to
defer the majority of cash compensation, effective immediately. 
About PURE Bioscience, Inc.
 PURE Bioscience, Inc. develops and
markets technology-based bioscience products that provide solutions
to numerous global health challenges, including Staph (MRSA) and
Carbapenem-resistant Enterobacteriaceae (CRE)/NDM-1+. PURE's
proprietary high efficacy/low toxicity bioscience technologies,
including its silver dihydrogen citrate-based antimicrobials,
represent innovative advances in diverse markets and lead today's
global trend toward industry and consumer use of "green" products
while providing competitive advantages in efficacy and safety.
Patented SDC is an electrolytically generated source of stabilized
ionic silver, which formulates well with other compounds. As a
platform technology, SDC is distinguished from competitors in the
marketplace because of its superior efficacy, reduced toxicity and
the inability of bacteria to form a resistance to it. PURE is
headquartered in El Cajon, California (San Diego metropolitan area).
Additional information on PURE is available at www.purebio.com. 
Forward-looking Statements
 This press release includes statements
that may constitute "forward-looking" statements, usually containing
the words "believe," "estimate," "expect," "intend," "project" or
similar expressions. These statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, the
Company's cash position and liquidity requirements, the Company's
failure to implement or otherwise achieve the benefits of its
proposed initiatives and business plans, acceptance of the Company's
current and future products and services in the marketplace, the
ability of the Company to develop effective new products and receive
regulatory approvals of such products, competitive factors,
dependence upon third-party vendors, and other risks detailed in the
Company's periodic report filings with the Securities and Exchange
Commission. By making these forward-looking statements, the Company
undertakes no obligation to update these statements for revisions or
changes after the date of this release. 
Investor Relations Contact:
Ron Both
Liolios Group, Inc.
Tel 949-574-3860
Press spacebar to pause and continue. Press esc to stop.